AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia
Shots:
- The P-III ASCEND study involves assessing of Calquence (acalabrutinib- 100mg- q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL
- The P-III ASCEND study resulted in meeting its 1EPs i.e- improvement in progression-free survival (PFS)- increment in the time for the next treatment and is safe & tolerable
- Calquence (acalabrutinib) is a BTK inhibitor- inhibiting its activity in B-cells- currently being evaluated in 26 studies by AstraZeneca & Acerta Pharma and has received FDA’s accelerated approval for MCL with one prior therapy in Oct’17
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com